Analysis

Obama's FDA Leaves Mark With Last-Minute Policy Blitz

Law360, New York (January 20, 2017, 8:39 PM EST) -- The U.S. Food and Drug Administration capped off the Obama administration with a flurry of bold policy statements on drug and device regulation, potentially influencing or hamstringing a Trump administration that has flirted with greatly relaxed oversight, attorneys say.

The last-minute blitz included more than 20 guidances that the FDA published during the final 10 days of Barack Obama's presidency. The guidances explored many important subjects, including biosimilars and promotion of prescription drugs, and in some cases were in danger of getting shelved if not published...
To view the full article, register now.